+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Synovial Sarcoma (SS) - Epidemiology Forecast To 2028

  • ID: 4855547
  • Report
  • November 2019
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 2
‘Synovial sarcoma (SS) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Synovial sarcoma Disease Understanding

Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8-10% of all soft tissue sarcomas (STS). SS can occur in almost any anatomic site, and, although it arises more often from the soft tissue, primary SS of the bone has also described. Despite its name, synovial sarcoma is not related to the synovial tissues that are a part of the joints. The disease starts most commonly in the legs or arms, but it can appear in any part of the body.

Synovial Sarcoma Epidemiology

The Synovial sarcoma (SS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Synovial sarcoma are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Synovial Sarcoma Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases , diagnosed incident cases, Site-specific incidence, gender-specific incidence, age-specific incidence, stage-specific incidence) scenario of Synovial Sarcoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, the total number of Incident cases of Synovia Sarcoma in 7 MM was found to be 2091 in the year 2017.

Report Scope
  • The report covers the descriptive overview of Synovial Sarcoma (SS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment pattern
  • Comprehensive insight has been provided into the epidemiology of the SS in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan
  • The Report helps to recognize the growth opportunities in the 7 MM with respect to the patient population
Epidemiology Segments
  • Total incident cases
  • Diagnosed incident cases
  • Site-specific incidence
  • Gender-specific incidence, Age-specific incidence
  • Stage-specific incidence
Key Strengths
  • 10 Years Forecast of Synovial Sarcoma
  • 7MM Coverage
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Synovial Sarcoma Market Overview at a Glance
2.1. Market Share (%) Distribution of Synovial Sarcoma Market in 2017
2.2. Market Share (%) Distribution of Synovial Sarcoma Market in 2028

3. Disease Background and Overview
3.1. Introduction
3.2. Subtypes
3.3. Causes and risk factors
3.4. Symptoms
3.5. Pathophysiology
3.6. Genetic aspect of synovial sarcoma
3.7. Grading and staging of soft tissue sarcoma
3.8. Diagnosis
3.9. Prognosis
3.10. Metastatic biomarkers in Synovial Sarcoma

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Incident Patient Population of Synovial Sarcoma
4.3. 7MM Diagnosed Incident Patient Population of Synovial Sarcoma

5. Country Wise-Epidemiology of Synovial Sarcoma
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Incident Cases of SS
5.1.3. Diagnosed Incidence of SS
5.1.4. Site Specific Diagnose incident cases of SS
5.1.5. Gender Specific diagnosed incident cases of SS
5.1.6. Age Specific diagnosed incident cases of SS
5.1.7. Stage Specific diagnosed Incident of cases of SS
5.2. EU5 Countries
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Total Incident Cases of SS
5.3.2. Diagnosed Incidence of SS
5.3.3. Site Specific diagnosed incident cases of SS
5.3.4. Gender Specific diagnosed incident cases of SS
5.3.5. Age Specific diagnosed incident cases of SS
5.3.6. Stage Specific diagnosed Incident of cases of SS
5.4. France
5.4.1. Total Incident Cases of SS
5.4.2. Diagnosed Incidence of SS
5.4.3. Site Specific diagnosed incident cases of SS
5.4.4. Gender Specific diagnosed incident cases of SS
5.4.5. Age Specific diagnosed incident cases of SS
5.4.6. Stage Specific diagnosed Incident of cases of SS
5.5. Italy
5.5.1. Total Incident Cases of SS
5.5.2. Diagnosed Incidence of SS
5.5.3. Site Specific diagnosed incident cases of SS
5.5.4. Gender Specific diagnosed incident cases of SS
5.5.5. Age Specific diagnosed incident cases of SS
5.5.6. Stage Specific diagnosed Incident of cases of SS
5.6. Spain
5.6.1. Total Incident Cases of SS
5.6.2. Diagnosed Incidence of SS
5.6.3. Site Specific diagnosed incident cases of SS
5.6.4. Gender Specific diagnosed incident cases of SS
5.6.5. Age Specific diagnosed incident cases of SS
5.6.6. Stage Specific diagnosed Incident of cases of SS
5.7. United Kingdom
5.7.1. Total Incident Cases of SS
5.7.2. Diagnosed Incidence of SS
5.7.3. Site Specific diagnosed incident cases of SS
5.7.4. Gender Specific incident cases of SS
5.7.5. Age Specific diagnosed incident cases of SS
5.7.6. Stage Specific diagnosed Incident of cases of SS
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Total Incident Cases of SS
5.8.3. Diagnosed Incidence of SS
5.8.4. Site Specific diagnosed incident cases of SS
5.8.5. Gender Specific diagnosed incident cases of SS
5.8.6. Age Specific diagnosed incident cases of SS
5.8.7. Stage Specific diagnosed Incident of cases of SS

6. Guidelines for Treatment/ Management of Soft-Tissue Sarcoma
6.1. European Society for Medical Oncology- European Reference Network for rare adult solid cancers Clinical Practice Guidelines (ESMO-EURACAN-CGP): for Soft-Tissue Sarcoma
6.2. UK Guidelines for Management of Soft-tissue Sarcomas
6.3. NICE Guidelines for Improving Diagnosis and Treatment of Soft-Tissue Sarcoma

7. Unmet needs

8. Appendix
8.1. Report Methodology

9. Capabilities

10. Disclaimer

11. About the Publisher

List of Tables
Table 1: Total Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
Table 2: Total Diagnosed Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
Table 3: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
Table 4: Diagnosed Incidence of SS in the United States (2017-2028)
Table 5: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
Table 6: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
Table 7: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
Table 8: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
Table 9: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
Table 10: Diagnosed Incidence of SS in Germany (2017-2028)
Table 11: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
Table 12: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
Table 13: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
Table 14: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
Table 15: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
Table 16: Diagnosed Incidence of SS in France (2017-2028)
Table 17: Site Specific diagnosed incident cases of SS in France (2017-2028)
Table 18: Gender Specific diagnosed incident cases of SS in France (2017-2028)
Table 19: Age Specific diagnosed incident cases of SS in France (2017-2028)
Table 20: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
Table 21: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
Table 22: Diagnosed Incidence of SS in Italy (2017-2028)
Table 23: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
Table 24: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
Table 25: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
Table 26: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
Table 27: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
Table 28: Diagnosed Incidence of SS in Spain (2017-2028)
Table 29: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
Table 30: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
Table 31: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
Table 32: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
Table 33: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
Table 34: Diagnosed Incidence of SS in the UK (2017-2028)
Table 35: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
Table 36: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
Table 37: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
Table 38: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
Table 39: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
Table 40: Diagnosed Incidence of SS in Japan (2017-2028)
Table 41: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
Table 42: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
Table 43: Age Specific incident cases of SS in Japan (2017-2028)
Table 44: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)

List of Figures
Figure 1: Subtypes of Synovial Sarcoma
Figure 2: Risk factors associated with Synovial Sarcoma
Figure 3: SYT-SSX fusion
Figure 4: Protein interaction domains involved in synovial sarcoma
Figure 5: Relationship between SS18, SS18-SSX and the BAF complex
Figure 6: Genomic changes associated with Synovial Sarcoma
Figure 7: Biomarkers in Synovial Sarcoma
Figure 8: Total Incident Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
Figure 9: Total Diagnosed Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
Figure 10: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
Figure 11: Diagnosed Incidence of SS in the United States (2017-2028)
Figure 12: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
Figure 13: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
Figure 14: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
Figure 15: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
Figure 16: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
Figure 17: Diagnosed Incidence of SS in Germany (2017-2028)
Figure 18: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
Figure 19: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
Figure 20: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
Figure 21: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
Figure 22: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
Figure 23: Diagnosed Incidence of SS in France (2017-2028)
Figure 24: Site Specific diagnosed incident cases of SS in France (2017-2028)
Figure 25: Gender Specific diagnosed incident cases of SS in France (2017-2028)
Figure 26: Age Specific diagnosed incident cases of SS in France (2017-2028)
Figure 27: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
Figure 28: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
Figure 29: Diagnosed Incidence of SS in Italy (2017-2028)
Figure 30: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
Figure 31: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
Figure 32: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
Figure 33: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
Figure 34: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
Figure 35: Diagnosed Incidence of SS in Spain (2017-2028)
Figure 36: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
Figure 37: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
Figure 38: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
Figure 39: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
Figure 40: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
Figure 41: Diagnosed Incidence of SS in the UK (2017-2028)
Figure 42: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
Figure 43: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
Figure 44: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
Figure 45: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
Figure 46: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
Figure 47: Diagnosed Incidence of SS in Japan (2017-2028)
Figure 48: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
Figure 49: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
Figure 50: Age Specific incident cases of SS in Japan (2017-2028)
Figure 51: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
Figure 52: The Multi-disciplinary judgment approach
Figure 53: Management of Localized clinically resectable STSs
Figure 54: Synovial Sarcoma unmet needs
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll